
浏览全部资源
扫码关注微信
1.湖南省职业病防治院妇产科,长沙 410007
2.长沙市第四医院妇产科,长沙 410006
3.湖南省中西医结合医院妇科,长沙 410006
主任医师。研究方向:妇科肿瘤及盆底功能障碍性疾病、妇科内分泌。E-mail:xiaotiqin7500@163.com
主任医师,硕士。研究方向:中西医结合治疗妇科。E-mail:47805047@qq.com
收稿:2026-01-21,
修回:2026-04-20,
录用:2026-04-20,
纸质出版:2026-05-15
移动端阅览
胡海玲,周琼姣,谢丹,等.ω-3多不饱和脂肪酸联合氯米芬对多囊卵巢综合征患者疗效、妊娠和安全性的影响 [J].中国药房,2026,37(09):1190-1194.
HU Hailing,ZHOU Qiongjiao,XIE Dan,et al.Effects of ω-3 polyunsaturated fatty acid combined with clomiphene on clinical efficacy, pregnancy and safety in patients with polycystic ovary syndrome[J].ZHONGGUO YAOFANG,2026,37(09):1190-1194.
胡海玲,周琼姣,谢丹,等.ω-3多不饱和脂肪酸联合氯米芬对多囊卵巢综合征患者疗效、妊娠和安全性的影响 [J].中国药房,2026,37(09):1190-1194. DOI: 10.6039/j.issn.1001-0408.2026.09.14.
HU Hailing,ZHOU Qiongjiao,XIE Dan,et al.Effects of ω-3 polyunsaturated fatty acid combined with clomiphene on clinical efficacy, pregnancy and safety in patients with polycystic ovary syndrome[J].ZHONGGUO YAOFANG,2026,37(09):1190-1194. DOI: 10.6039/j.issn.1001-0408.2026.09.14.
目的
2
探讨ω-3多不饱和脂肪酸(ω-3PUFA)联合氯米芬对多囊卵巢综合征(PCOS)患者临床疗效、妊娠和安全性的影响。
方法
2
采用回顾性研究方法,纳入2022年1月至2023年12月在湖南省职业病防治院妇产科接受治疗的PCOS患者112例,根据不同干预方案分为单药治疗组(60例)和联合用药组(52例)。单药治疗组患者给予氯米芬治疗,联合用药组患者在氯米芬基础上联合ω-3PUFA干预。比较两组患者的临床疗效、妊娠情况、不良反应发生情况以及治疗前后卵巢功能和氧化应激指标。
结果
2
联合用药组患者的总有效率(90.38% vs. 71.67%)、排卵率(84.62% vs. 61.67%)、妊娠率(51.92% vs. 26.67%)均显著高于单药治疗组(
P
<0.05)。治疗前,两组患者各项卵巢功能和氧化应激指标比较,差异均无统计学意义(
P
>0.05);相较于治疗前,两组患者治疗12周后的血清抗米勒管激素水平、抑制素B浓度和囊性卵泡数均显著降低或减少(
P
<0.05),子宫内膜厚度均显著增加(
P
<0.05),血清丙二醛和晚期氧化蛋白产物水平均显著降低(
P
<0.05),血清超氧化物歧化酶和谷胱甘肽过氧化物酶活性均显著升高(
P
<0.05),其中联合用药组的改善幅度均显著大于单药治疗组(
P
<0.05);两组患者治疗后的卵巢体积均显著小于治疗前(
P
<0.05),但组间比较差异无统计学意义(
P
>0.05)。两组患者治疗期间不良反应总发生率比较,差异无统计学意义(
P
>0.05)。
结论
2
ω-3PUFA联合氯米芬治疗PCOS的疗效确切,可有效减轻机体氧化应激反应,改善卵巢功能,提高排卵率及妊娠率。
OBJECTIVE
2
To investigate the effects of ω-3 polyunsaturated fatty acid (ω-3PUFA) combined with clomiphene on clinical efficacy, pregnancy and safety in patients with polycystic ovary syndrome (PCOS).
METHODS
2
A retrospective analysis was performed on the clinical data of 112 PCOS patients who received treatment in Dept. of Obstetrics and Gynecology of Hunan Prevention and Treatment Institute for Occupational Diseases from January 2022 to December 2023. According to the different treatment regimens, the patients were divided into single-drug group (60 cases) and drug-combination group (52 cases). Single-drug group was given clomiphene orally, and drug-combination group was given clomiphene+ω-3PUFA. Clinical efficacy, pregnancy status and the occurrence of adverse drug reaction (ADR) as well as ovarian function and oxidative stress indexes before and after treatment were compared between 2 groups.
RESULTS
2
The overall response rate (90.38% vs. 71.67%), ovulation rate (84.62% vs. 61.67%), and pregnancy rate (51.92% vs. 26.67%) were all markedly higher in drug combination group than single drug group (
P
<0.05). Before treatment, there was no statistical significance in ovarian function and oxidative stress indexes between 2 groups (
P
>0.05). Compared with before treatment, serum anti-Müllerian hormone levels, inhibin B concentr
ations, and the number of cystic follicles in 2 groups were decreased significantly after 12 weeks of treatment (
P
<0.05). The endometrial thickness increased significantly (
P
<0.05), while the serum levels of malondialdehyde and advanced oxidation protein products decreased significantly (
P
<0.05); the activities of serum superoxide dismutase and glutathione peroxidase increased significantly (
P
<0.05); the improvement of drug combination group was significantly better than single drug group (
P
<0.05). The ovarian volumes in both groups were significantly smaller after treatment compared to before treatment (
P
<0.05), but there was no statistically significant difference between the two groups (
P
>0.05). There was no significant difference in the overall incidence of ADR between the two groups during the treatment (
P
>0.05).
CONCLUSIONS
2
The combination of ω-3PUFA and clomiphene has a definite therapeutic effect on PCOS, which can effectively reduce the body’s oxidative stress response, improve ovarian function, and increase ovulation and pregnancy rates.
李凯俊 , 张燊 , 何帆 . 基于液相色谱-串联质谱的激素测定平台助力多囊卵巢综合征的精准诊疗 [J ] . 西南医科大学学报 , 2024 , 47 ( 3 ): 221 - 225 .
孙守萍 , 辛芳芳 , 陈晶 . 多囊卵巢综合征患者血清内脂素、脂联素水平与2型糖尿病的相关性 [J ] . 实验与检验医学 , 2021 , 39 ( 3 ): 665 - 668,672 .
ZENG X , XIE Y J , LIU Y T , et al . Polycystic ovarian syndrome:correlation between hyperandrogenism,insulin resistance and obesity [J ] . Clin Chim Acta , 2020 , 502 : 214 - 221 .
高玲 , 龙宇航 , 黄荷凤 . 多囊卵巢综合征加重心血管损伤新机制研究 [J ] . 中华内分泌代谢杂志 , 2024 , 40 ( 4 ): 275 - 282 .
中华医学会妇产科学分会内分泌学组及指南专家组 . 多囊卵巢综合征中国诊疗指南 [J ] . 中华妇产科杂志 , 2018 , 53 ( 1 ): 2 - 6 .
MUHAMMED SAEED A A , NOREEN S , AWLQADR F H , et al . Nutritional and herbal interventions for polycystic ovary syndrome (PCOS):a comprehensive review of dietary approaches,macronutrient impact,and herbal medicine in management [J ] . J Health Popul Nutr , 2025 , 44 ( 1 ): 143 .
MELO V , SILVA T , SILVA T , et al . Omega-3 supplementation in the treatment of polycystic ovary syndrome (PCOS):a review of clinical trials and cohort [J ] . Endocr Regul , 2022 , 56 ( 1 ): 66 - 79 .
尹婧雯 , 杨纨 , 于多 , 等 . 多囊卵巢综合征评估和管理国际循证指南推荐建议:2023年版 [J ] . 中华生殖与避孕杂志 , 2023 , 43 ( 11 ): 1099 - 1113 .
朱雪莹 , 张路 , 黄欲晓 , 等 . 活血补肾配方颗粒对多囊卵巢综合征不孕症患者促排卵周期子宫内膜容受性的影响 [J ] . 国际中医中药杂志 , 2024 , 46 ( 9 ): 1128 - 1133 .
皋文君 , 刘砚燕 , 袁长蓉 . 国际肿瘤化疗药物不良反应评价系统:通用不良反应术语标准4. 0版 [J ] . 肿瘤 , 2012 , 32 ( 2 ): 142 - 144 .
AL WATTAR B H , FISHER M , BEVINGTON L , et al . Clinical practice guidelines on the diagnosis and management of polycystic ovary syndrome:a systematic review and quality assessment study [J ] . J Clin Endocrinol Metab , 2021 , 106 ( 8 ): 2436 - 2446 .
ARMANINI D , BOSCARO M , BORDIN L , et al . Controversies in the pathogenesis,diagnosis and treatment of PCOS:focus on insulin resistance,inflammation,and hyperandrogenism [J ] . Int J Mol Sci , 2022 , 23 ( 8 ): 4110 .
BANSAL S , GOYAL M , SHARMA C , et al . Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome:a randomized controlled trial [J ] . Int J Gynecol Obstet , 2021 , 152 ( 3 ): 345 - 350 .
高洁凡 , 王东晖 , 宋阳阳 , 等 . 来曲唑联合克罗米芬治疗多囊卵巢综合征患者的疗效及对排卵、妊娠情况的影响 [J ] . 中国妇产科临床杂志 , 2022 , 23 ( 3 ): 266 - 268 .
多囊卵巢综合征相关不孕治疗及生育保护共识专家组 , 中华预防医学会生育力保护分会生殖内分泌生育保护学组 . 多囊卵巢综合征相关不孕治疗及生育保护共识 [J ] . 生殖医学杂志 , 2020 , 29 ( 7 ): 843 - 851 .
BARREA L , ARNONE A , ANNUNZIATA G , et al . Adherence to the Mediterranean diet,dietary patterns and body composition in women with polycystic ovary syndrome (PCOS) [J ] . Nutrients , 2019 , 11 ( 10 ): 2278 .
李明月 , 田烨 , 张慧英 , 等 . 多不饱和脂肪酸对多囊卵巢综合征的影响及其机制 [J ] . 中华生殖与避孕杂志 , 2021 , 41 ( 12 ): 1139 - 1142 .
YUAN J L , WEN X M , JIA M . Efficacy of omega-3 polyunsaturated fatty acids on hormones,oxidative stress,and inflammatory parameters among polycystic ovary syndrome:a systematic review and meta-analysis [J ] . Ann Palliat Med , 2021 , 10 ( 8 ): 8991 - 9001 .
ZHOU J , ZUO W T , TAN Y , et al . Effects of n-3 polyunsaturated fatty acid on metabolic status in women with polycystic ovary syndrome:a meta-analysis of randomized controlled trials [J ] . J Ovarian Res , 2023 , 16 ( 1 ): 54 .
ZAREZADEH R , MEHDIZADEH A , LEROY J L M R , et al . Action mechanisms of n-3 polyunsaturated fatty acids on the oocyte maturation and developmental competence:potential advantages and disadvantages [J ] . J Cell Physiol , 2019 , 234 ( 2 ): 1016 - 1029 .
李欢欢 , 张玉齐 , 吕海宏 . 氧化应激增加多囊卵巢综合征患者心血管疾病风险的研究进展 [J ] . 基础医学与临床 , 2022 , 42 ( 12 ): 1950 - 1954 .
张晗 , 吴林玲 , 闫颖 . 多囊卵巢综合征氧化应激及标志物的研究进展 [J ] . 中国医药导报 , 2020 , 17 ( 5 ): 31 - 34 .
0
浏览量
5
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621